All In Biotech

Drug Trial Radar · NCT01546038

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME

Last checked: Nov 19, 2026Latest source record: Mar 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

255

Actual

Start

Jun 27, 2012

Primary completion

Jan 3, 2017

Study completion Mar 4, 2019

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 7, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with standard agents used to treat these diseases.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • PF-04449913Drug

    PF-04449913 administered orally and continuously for 28-days.

  • Low dose ARA-C (LDAC)Drug

    Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.

  • PF-04449913Drug

    PF-04449913 administered orally and continuously for 28 days.

  • DecitabineDrug

    Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days

  • PF-04449913Drug

    PF-04449913 administered orally and continuously for 28 days

  • DaunorubicinDrug

    Daunorubicin given using 60 mg/m2 for 3-days

  • CytarabineDrug

    Cytarabine 100 mg/m2 on days 1 through 7

  • PF-04449913Drug

    PF-04449913 administered orally and continuously for 28 days

  • DaunorubicinDrug

    Daunorubicin given using 60 mg/m2 for 3-days

  • CytarabineDrug

    Cytarabine 100 mg/m2 on days 1 through 7

  • PF-04449913Drug

    PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)

  • Low dose ARA-C (LDAC)Drug

    Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose-limiting Toxicities (DLTs) at Phase 1BTime frame: Arms A and B: Cycle 1, Day 1 to Day 28; Arm C: Cycle 1, Day -3 to Day 21 or to Day 28 depending on when the next chemotherapy cycle was started
  2. Percentage of Participants With Complete Response (CR) at Phase 2 FitTime frame: 4 years
  3. Overall Survival (OS) at Phase 2 UnfitTime frame: Randomization to Follow-up (4 years)

Locations

81 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • UC San Diego Moores Cancer Center - Investigational Drug Services

    La Jolla, California

  • UC San Diego Medical Center - La Jolla

    La Jolla, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Keck Hospital of USC

    Los Angeles, California

  • LAC & USC Medical Center

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center / Investigational Drug Services

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center Drug Information Center

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • UCLA Drug lnformation/lnvestigational Drugs

    Los Angeles, California

  • UCLA Hematology/Oncology Clinic

    Los Angeles, California

  • UC San Diego Medical Center - Hillcrest

    San Diego, California

  • University of Colorado Denver

    Aurora, Colorado

  • University of Colorado Hospital

    Aurora, Colorado

  • H.Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • Investigational Drug Service, Emory University Clinic

    Atlanta, Georgia

  • The Emory Clinic

    Atlanta, Georgia

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Northwestern Medical Faculty Foundation

    Chicago, Illinois

  • Northwestern Medicine Developmental Therapeutics Institute

    Chicago, Illinois

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • The University of Chicago Medical Center

    Chicago, Illinois

  • The University of Chicago's Medical Center

    Chicago, Illinois

  • University of Kansas Clinical Research Center

    Fairway, Kansas

  • University of Kansas Hospital

    Kansas City, Kansas

  • University of Kansas Cancer Center and Medical Pavilion

    Westwood, Kansas

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute (DFCI)

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center Clinical Trials Office

    Ann Arbor, Michigan

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Siteman Cancer Center - West County

    Creve Coeur, Missouri

  • Barnes Jewish Hospital North Campus

    St Louis, Missouri

  • Barnes-Jewish Hospital

    St Louis, Missouri

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.